(CercleFinance.com) – The stock ended the day up sharply (3.5%) benefiting from the positive analysis of Credit Suisse. Despite this increase, the value posted a decline of 2% over the week.
The analyst confirms his Outperformance advice and his target price of 380 CHF.
In 2022, the Swiss healthcare group saw its earnings per share (BPT) from basic activities increase by 5% in local currencies, to 20.30 Swiss francs, for a turnover of nearly 63.3 billion, up 2% at constant exchange rates (CER).
Credit Suisse estimates that second-half earnings were 3% below consensus but 3% above Credit Suisse’s forecast.
Credit Suisse is increasing Vabysmo’s sales pace and is now aiming for a maximum sales potential of $5.5 billion.
‘ We are also updating our currency assumptions, which reduces sales and earnings by around 3%. Overall, we are reducing 2023-27 sales by 1.6% and core EPS by 2%,” Credit Suisse points out.
Copyright (c) 2023 CercleFinance.com. All rights reserved.